

REMARKS

In the Office Communication dated August 10, 2007, the Examiner states that the reply filed on May 3, 2007 is not fully responsive because Applicants have not identify the peptide sequence, HDEL, with its sequence identifier, every time this peptide sequence appears in the specification.

In response, Applicants have reviewed the specification in its entirety and submit the foregoing amendments to insert the sequence identifier (i.e., SEQ ID NO: 1) for the HDEL peptide in the specification wherever appropriate. It is noted, however, there are instances where the term "HDEL" appears in the specification, yet is not followed by the sequence identifier of SEQ ID NO: 1. For example, on page 42, line 8, the specification refers to "mannosidase-HDEL" and "mannosidase IB-HDEL" which, as well understood by those skilled in the art, mean a mannosidase and a mannosidase IB that are engineered to contain an HDEL signal, respectively. However, Applicants have not added the identifier of "SEQ ID NO: 1" after "HDEL" here, as it could be misunderstood to be the identifier for the engineered mannosidases.

It is firmly believed that the foregoing amendments fully address the Examiner's objection, and that the subject application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P. C.
400 Garden City Plaza-STE 300
Garden City, New York 11530
Telephone: 516-742-4343
XZ:ab